anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The cosmetic preparation is used as a mask. It has simultaneously deep cleaning, feeding and tonic effect, smoothens and refreshes the skin, and can be used only in the zones of wrinkle formation. The preparation forms a food film which can be removed in dry, after which the face has only to be washed with cool water and there is no need of any application of feeding and protection cream. There are no unwanted side effects and causes no allergic reactions. Clear antiphlogistic and therapeutic effect is attained on any manifestations of Acne vulgaris. The cosmetic preparation is a dry lactic product, containing, in wt.%: low lactose wholesome or skimmed cows' milk from 48 to 70, low lactose skimmed milk hydrolysate of over 95% degraded lactic casein containing oligo-, di- and tri-peptides and free amino acids from 8 to 20; low lactose wholesome or skimmed milk, fermented with selected strains of Lactobacillus delbrueckii subsp. bulgaricus, containing up to 950 mln/g live and latent cells and to 160 mg. % free amino acids from 4.0 to 8.5, pectine about 1, saccharose from 11 to 18 and optionally low lactose and galactose-free protein precipitate from 0 to 15. The means contains no preservatives. 1 claim
PURPOSE: A method of producing sustained release nanoparticles in which a luteinizing hormone releasing hormone(LHRH) analogue as a physiologically active substance is included by use of a biodegradable polymer as a carrier, is provided. The nanoparticles enable continuous release of the LHRH analogue in an effective concentration for a specified period when administered to a human body and thus can effectively used in the treatment of diseases such as prostate cancer, endometriosis, hysteromyoma, etc. CONSTITUTION: A LHRH analogue and a biodegradable polymer are dissolved in acetic acid, formic acid or a mixture thereof and dried by spraying compressed air of 300 to 500Nl/h at 60 to 90deg.C for 10 to 12hr under reduced pressure. The sustained release nanoparticles contain 0.1 to 25%(w/w) of LHRH analogue, based on the biodegradable polymer. The LHRH analogue is selected from a LHRH agonist and a LHRH antagonist. The biodegradable polymer is at least one selected from polylactide, polyglycolide, poly(lactide-glycolide), polyorthoester, polyanhydride, poly(amino acid), poly(hydroxybutyric acid), polycaprolactone and poly(alkylcarbonate).
Participants will receive donepezil 5 milligram (mg), once daily in the evening during the titration phase and then the dose will be increased to 10 mg at Week 4 during the double blind period. During the maintenance period, dose reduction to 5 mg/day will be permitted only when 10 mg/day is intolerable due to adverse events.
BACKGROUND AND AIMS: The clinical spectrum of human infection by HEV ranges from asymptomatic to severe acute hepatitis. Furthermore, HEV can cause diverse neurological manifestations, especially Parsonage-Turner syndrome. Here, we used a large-scale human genomic approach to search for genetic determinants of severe clinical presentations of HEV infection.
APPROACH AND RESULTS: We performed whole genome sequencing in 3 groups of study participants with PCR-proven acute HEV infection: (1) 24 patients with symptomatic acute hepatitis E; (2) 12 patients with HEV-associated Parsonage-Turner syndrome; and (3) 16 asymptomatic blood donors (controls). For variant calling and annotation, we used GATK4 best practices followed by Variant Effect Predictor (VEP) and Annovar. For variant classification, we implemented the American College of Medical Genetics and Genomics/Association for Molecular Pathology Bayesian classification framework in R. Variants with a probability of pathogenicity >0.9 were considered damaging. We used all genes with at least 1 damaging variant as input for pathway enrichment analyses.We observed a significant enrichment of type I interferon response pathways in the symptomatic hepatitis group: 10 out of 24 patients carried a damaging variant in one of 9 genes encoding either intracellular viral sensors ( IFIH1 , DDX58 , TLR3 , POLR3B , POLR3C ) or other molecules involved in type I interferon response [interferon regulatory factor 7 ( IRF7 ), MYD88 , OAS3 , GAPDH ]. We did not find any enriched pathway in the Parsonage-Turner syndrome group or in the controls.
CONCLUSIONS: Our results highlight the essential role of type I interferon in preventing symptomatic acute hepatitis E.
The invention discloses a traditional Chinese medicine for treating the transient ischemic attack caused by qi deficiency and blood stasis and a preparation method. The traditional Chinese medicine is characterized by being prepared from, by weight, 7-19 parts of Acranthera Arn. ex Meissn., 15-35 parts of Limonium bicolor, 15-35 parts of Hamamelis mollis Oliver, 7-19 parts of roots of Intermediate Peashrub., 7-19 parts of roots or full grass of Spiranthes australis Lindl., 4-12 parts of lentinus edodes, 15-35 parts of Crotalaria ferruginea Grah. ex Benth., 1-9 parts of Antigramma sibiricus J. Sm., 15-35 parts of Mucuna sempervirens Hemsl, 4-12 parts of Oxalis acetosella L., 6-18 parts of Aucuba chinensis Benth. Subsp. Omeiensis (Fang) F, 3-11 parts of crocussativus, 15-35 parts of Lysimachia paridiformis Franch.var.Stenophylla Franch., 4-12 parts of Plagiopus oederi (Brid.) Limpr., 15-35 parts of aralia elata and 2-10 parts of liquorice roots. The traditional Chinese medicine can effectively treat the transient ischemic attack caused by qi deficiency and blood stasis; over the years, the effective rate reaches 96% after the traditional Chinese medicine is used by multiple patients, and cerebral apoplexy is prevented.
Patients undergo stereotactic biopsy (to confirm the diagnosis) and placement of a catheter within the tumor, followed by MV-CEA IT through the catheter over 10 minutes on day 1. Patients then undergo en block resection of their tumor with computer-assisted stereotactic techniques on day 5, followed by MV-CEA administered around the tumor bed.
TITLE: Translation and validation of Bristol Female lower urinary tract symptoms (BFLUTS) questionnaire for Nepali speaking women Introduction: Bristol female lower urinary tract symptoms questionnaire (BFLUTS) was designed to identify the lower urinary tract symptoms (LUTS) in women. It aids in determining the severity of lower urinary tract symptoms and how they affect sexual function and quality of life.It can be employed in research and therapeutic practice. It is not available in Nepali version. As a result, our goal is to translate and validate the BFLUTS questionnaire in Nepali.
METHODS: The BFLUTS questionnaire has been translated into Nepali. From March 1, 2020 to February 28, 2021, 225 Nepalese patients with lower urinary tract symptoms were evaluated using a Nepali version of the BFLUTS questionnaire adapted from the English version. Internal consistency, test-retest reliability, validity, and change responsiveness were all assessed.
RESULTS: A total of 225   patients were enrolled in the study. The missing data was less than 2%. The Nepali version of the BFLUTS questionnaire showed good reliability (? = 0.76; ICC= 0.934). Test-retest reliability was assessed with weighted kappa (?) ranging from 0.71 to 0.83.It showed good sensitive to change before and after the treatment. Mean BFLUTS scores correlated strongly with the symptomsof lower urinary tract symptoms reported in the bladder diary with ? ranging from 0.689to 0.859.
CONCLUSIONS: The Nepali version of BFLUTS questionnaire is a reliable, valid and consistent for measuring lower urinary tract symptoms and their effect on sexual function and quality of life.
A system and associated method provides an assessment of patient's heart health status based on past medical data. The system has a collection system, a processing system, a profiling system, and a user tools system. The collection system collects data from at least one data source having the past medical data of a plurality of patients. The processing system processes unstructured data to extract information related to patient health at different points in time. The profiling system develops a classifier based on the extracted information and other collected data. The profiling system further categorizes the extracted information into one of a plurality of health statuses at the different points in time. The user tools system generates a user interface comprising the plurality of health statuses at the different points in time. The health statuses relate to a compensated or decompensated status of the patient's heart.
Provided herein are nucleic acids encoding human NMDA receptor protein subunits and the proteins encoded thereby. In one aspect of the invention, the nucleic acids encode provides In a preferred embodiment, the invention nucleic acids encode MNDAR1, NMDAR2A, NMDAR2B, NMDAR2C and NMDAR2D subunits of human NMDA receptors. The disclosed nucleic acids are also useful as probes, thus enabling those skilled in the art, to identify and isolate related human receptor subunits. Functional glutamate receptors can be assembled, in accordance with the present invention, from a plurality of one type of NMDA receptor subunit protein (homomeric) or from a mixture of two or more types of subunit proteins (heteromeric). Also provided are methods for using the disclosed receptor subunits to identify and characterize compounds which affect the function of such receptors, e.g., agonists, antagonists, and modulators of glutamate receptor function. Methods for determining whether unknown protein(s) are functional as NMDA receptor subunits are also provided.
Subjects will receive single oral dose of 100 milligram (mg) of Casopitant. There will be wash out period of 7 days.
NEW MATERIAL:A compound shown by the formula I (X is H, or halogen; R is H, or lower alkyl; Y is group shown by the formula II or group shown by the formula III). EXAMPLE:1,3,4,5,6,7-Hexahydro-2,5-benzothiazonin. USE:A drug for circulatory system. Having an inhibitoy action on blood platelet aggregation, an inhibitory action on contraction of extracted intestine, vasodilating action on crown blood, etc. PREPARATION:A phenylthiomorpholin-3-one shown by the formula IV is reacted with a methyl halide such as methyl iodide, methyl bromide, etc. and silver perchlorate, silver 4-fluoroborate, Meerwein reagent, etc. to give a methylsulfonium salt shown by the formula V (Z(-) is inorganic anion). It is heated in the presence of a base (e.g., sodium amide, etc.) to give a compound shown by the formula I .
Women in this group will receive 25mcg of vaginal misoprostol every 4 hours up to a maximum of 5 doses. At the same time a 16French Foley catheter will be inserted through the internal os with visualization of the cervix by sterile speculum examination. The catheter balloon will be inflated with 30 ml of sterile normal saline solution and then the catheter will be taped with gentle traction to the inner thigh of the patient until spontaneous expulsion. If this does not occur, the catheter will be deflated and removed after 12 hours. Misoprostol will be stopped in case of a favorable cervix or if the patient is in active labor. In case of no progression after 5 doses of misoprostol, intravenous oxytocin will be perfused 4 hours after the last dose of misoprostol.
OBJECTIVE: To determine the association between non-adherence to long term chronic obstructive pulmonary disease (COPD) medications and COPD related emergency department (ED) visits and hospitalizations in patients with incident COPD, utilizing time varying measures of adherence as well as accounting for time-varying confounding impacted by prior adherence.
STUDY DESIGN AND SETTING: We conducted a population-based retrospective cohort study between 2007-2017 among individuals aged 66 years and older with incident COPD using multiple linked administrative health databases from the province of Ontario, Canada. Adherence to COPD medications was measured using time varying proportion of days covered based on insurance claims for medications dispensed at community pharmacies. The parametric g-formula was used to assess the association between time-varying adherence (in the last 90-days) to COPD medications and risk of COPD related hospitalizations and ED visits while accounting for time varying confounding by COPD severity.
RESULTS: Overall, 60,251 individuals with incident COPD were included; mean age was 76 (SD 7) and 59% were male. Mean adherence over the entire follow-up was 23% (SD 0.3). There were 7248 (12%) COPD related ED visits (2.8 events per 100 person years [PY]) and 9188 (15%) COPD related hospitalizations (3.5 events per 100 PY). Compared to those with 0% 90-day adherence, those with adherence between 1-33% had a 19% decreased risk of COPD related ED visits (adjusted risk ratio[aRR]:0.81, 95% confidence interval [CI]:0.78-0.83), those with adherence between 34%-67% had a 18% decreased risk (aRR: 0.82, 95% CI: 0.77-0.85) while those with 68%-100% 90-day adherence had a 63% increased risk of COPD related ED visits (aRR: 1.63, 95% CI: 1.47-1.78). Nearly identical results were obtained for COPD specific hospitalizations.
CONCLUSION: After accounting for time varying confounding by COPD severity, the highest time varying 90-days adherence was associated with an increased risk of both COPD related ED visits and hospitalizations compared to the lowest adherence categories. Differences in COPD severity between adherence categories, perception of need for medication management in the higher adherence categories, and potential residual confounding makes it difficult to disentangle the independent effects of adherence from the severity of the condition itself.
The COVID-19 pandemic deeply affected the lives of children and young people; studies report adverse effects on mental, physical, and social well-being. However, the impact of the pandemic on obesity care for children received little attention. The aim of this study was to gain insight into the challenges youth healthcare nurses experienced and to describe implications for future obesity care and policy. We conducted interviews, participant observations, and a group session with youth healthcare nurses during the pandemic in Amsterdam, the Netherlands. Youth healthcare nurses reported a deterioration in the problems of children and young people who were already in the highest classification for pediatric obesity, such as increased weight gain, mental health problems, and socio-economic problems. The nurses experienced immense challenges while trying to provide obesity care, such as a decrease in face-to-face contact with youth and their families, as well as loss of continuity of care. It is important to reconnect with these families, invest in a trusted relationship with youth receiving obesity care, and prioritize available and accessible obesity care for those who need it the most.
The present invention relates to a health food for dietetic therapy and stomach protection. The present invention relates to stomach-protecting paste, which is characterized in that the stomach-protecting paste is a pasty food which is prepared from a small quantity of seasoning medicines, poultry eggs and sorghum liquor. The stomach-protecting paste can eliminate pylorus spirabacteria, and chronic gastritis, stomach canker and duodenal ampulla canker quickly restore to normal states by activating blood circulation to dissipate blood stasis, relieving inflammation, alleviating pain, removing decomposition, generating muscles and protecting gastric mucosa. For epigastric discomfort, heartburn, acid reflux, pain during starvation and other symptoms, as long as the stomach-protecting paste is taken according to the explanation of a label, satisfying effect can be achieved. The stomach-protecting paste does not have any side effect ordinarily. The stomach-protecting paste can be processed and produced by health food factories with conditions. The present invention has the advantages of wide application, arresting benefit, easy popularization, portability, convenient administration, safety, reliability and no side effect.
As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Insulin Aspart in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

In a 6-month study with a 6-month extension in adult subjects with type 1 diabetes, 99.8% of patients who received Insulin Aspart were positive for anti-insulin antibodies (AIA) at least once during the study, including 97.2% that were positive at baseline. A total of 92.1% of patients who received Insulin Aspart were positive for anti-drug antibodies (ADA) at least once during the study, including 64.6% that were positive at baseline.

In a phase 3 type 1 diabetes clinical trial of Insulin Aspart, initial increase in titers of antibodies to insulin, followed by a decrease to baseline values, was observed in regular human insulin and insulin aspart treatment groups with similar incidences. These antibodies did not cause deterioration in glycemic control or necessitate increases in insulin dose.
Patients receive sapanisertib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who are non-responders and in PR at the end of course 4 may receive sapanisertib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely - to neurology, vertebrology and restorative medicine. The method involves drug-induced analgetic blockade. The blockage is combined with interstitial carpain electrophoresis of an anaesthetic injection place. Current intensity for electrophoresis is 4-7 mA. Duration of a procedure is 10-12 minutes. The procedures are daily; the therapeutic course is 12-15 procedures. ^ EFFECT: method provides managing pain syndrome, reducing the volume of hernial bulge, restoring radicular conductivity, increasing duration of remission. ^ 1 ex, 3 dwg
Patients receive PXD101 IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 6-12 months in the absence of disease progression or unacceptable toxicity.
Carotenoids are purified by contacting them with water-soluble surface-active agents and then washing them with water.  The carotenoid may be contacted with the surface-active agent and simultaneously or subsequently with water, allowed or caused to crystallize, and the resulting crystals then washed with water. The surface-active agent may be one which forms with the compound a homogeneous phase in the form of a solution or melt, and this mixture may be added to water or have water added to it.  The purification may be carried out under an inert atmosphere, and an antioxidant may be present. In examples axerophthene is purified with polyoxyethylene castor oil, diisobutylnaphthalene sulphonate, N - lauryl - N - methylimidazolium methyl-sulphate, oleic diethanolamide and polyoxyethylated oleic ethanolamide.ALSO:Vitamin-A compounds and other carotenoids are purified by contacting them with water-soluble surface active agents and then washing them with water.  The compound may be contacted with the surface active agent and simultaneously or subsequently with water, and then washed with water.  The surface active agent may be one which forms with the compound a homogeneous phase in the form of a solution or melt, and this mixture may be added to water or have water added to it. The purification may be carried out under an inert atmosphere, and an antioxidant may be present.  In examples the compounds purified are axerophthene, Vitamin-A alcohol, Vitamin-A acetate, the methyl ester of Vitamin-A acid, retinene, b -carotene and 13-[21,61,61-trimethyl-cyclohexene - (11) - yl - (11)] - 3,7,11 - trimethyl-tridecahexene - (2,4,6,8,10,12) - acid - (1) - ethyl ester, and the surface active agents are polyoxyethylene castor oil, diisobutylnaphthalene sulphonate, soap, polyoxyethylene-sorbitan oleate, polyoxyethylenesorbitan laurate, N-lauryl-N-methylimidazolium methyl sulphate, oleic diethanolamide, polyoxyethylated oleic ethanolamine trimethylstearyl ammonium methosulphite, the disodium salt of ethylene diamine tetraacetic acid, turkey red oil, 2,4,6-trimethyl-4-stearyl-morpholinium methosulphate, polyoxyethylated oleylamine, the sodium salt of dinaphthylmethane-b ,b 1 disulphonic acid, polyoxyethylated coconut oil fatty alcohol, the sodium salt of sulphosuccinic diisooctyl ester, benzylpyridinium chloride, dimethylaniline dodecylbenzene sulphonate, sodium salts of acid sulphuric acid esters of coconut oil alcohols, triethanolamine monostearate, sodium salts of C12-C18 alkylsulphonic acids, polyoxyethylated isooctylphenol and sulphite waste liquor.
The invention discloses an iridium ferrocene pyridine complex with a half sandwich structure, a preparation method and anticancer application thereof. The structural formula is shown as a formula (I), R is methyl, phenyl or biphenyl, and double bonds are in cis and trans configurations. The growth inhibition rate of the target complex on human alveolar basement epithelial cancer cells, cervical cancer cells and human lung normal epithelial cells is tested, and the contrast finds that the target complex shows good anticancer activity, so that the synergistic anticancer effect of the ferrocene and the metal iridium complex is proved. The substituent R is methyl → phenyl → biphenyl, the activity of the complex is effectively improved, and the improvement of the electron donating capability of the ligand is proved to be beneficial to the improvement of the anticancer activity of the complex.In addition, the trans-configured complexes also exhibit higher activity. The target complex may accumulate in lysosomes within a549 cells and cause lysosomal damage, leading to cancer cell death. The complex exhibits some selectivity between normal and cancer cells.
Use only iGetBetter for the 3 months preceding surgery. After surgery, you will be given a new, Post-Op program to use for 2-3 months. For the first 3 weeks, you will only use iGetBetter. After those 3 weeks, you will receive outpatient physical therapy in addition to iGetBetter, approximately twice per week for the next 6-8 weeks.
This is an open-label, prospective, non-placebo controlled pilot study. 15 subjects with a diagnosis of restless legs syndrome (ICSD-3 diagnostic criteria) will be recruited from OSF Healthcare Saint Francis Medical Center sleep center and Illinois Neurological Institute. RLS/WED patients who meet inclusion and exclusion criteria during the initial clinic visit will be offered study participation. Standard treatment options will be discussed prior to the enrollment. Patients will be reassured that not participating in the study will not affect the future care they receive at OSF HealthCare. The potential risks and benefits of the study will be provided and, if the patient is interested, informed consent will be obtained. If the subject withdraws consent or does not finish both pre and post evaluation, we will replace the subject with another new recruit. The subject will come to the clinic for 2 visits, a pre-magnesium visit and a post-magnesium visit. Following the completion of the pre-magnesium visit, the subject will be given 200 mg elemental magnesium daily (will be instructed to take with food at dinner) for 8 weeks. Both Visits the following study procedures will be performed: magnesium level, (International Restless Legs Syndrome) IRLS scale, Kohnen Restless Legs Syndrome Quality of Life Instrument (KRLS-QOL) scale and (Multiple Suggested Immobilization (MSI) test. The post magnesium visit will be schedule at the completion of the 8 week dose of magnesium.